## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no access to full manuscript, figures, tables, or supplementary materials
- **Shared manuscript claim summary** The authors propose a reversible upper confidence bound (UCB) reinforcement learning algorithm to reduce the computational cost of molecular docking against conformational ensembles of intrinsically disordered proteins (IDPs), demonstrated on the transcription factor c-Myc, with reported reductions in average docking number per ligand and minimal performance loss.
- **Visible evidence base** Abstract text only; no quantitative results, methodological details, or validation data are provided
- **Missing materials affecting confidence** Full methods, algorithm pseudocode, docking software and parameters, ensemble generation protocol, benchmark details, performance metrics, comparison baselines, statistical analyses, and any figures or tables

## Reviewer
- **Overall assessment** The abstract presents a conceptually interesting application of reinforcement learning to a practical bottleneck in IDP virtual screening. The core idea, using a UCB-style algorithm to prioritize ligand conformations near a decision boundary, is plausible and potentially useful. However, the abstract provides insufficient technical detail and quantitative evidence to evaluate the method's validity, generalizability, or comparative advantage. The claim of "greatly reduced" docking number with "merely slightly affected" performance is not substantiated by any numbers, and the absence of baseline comparisons or statistical rigor weakens the case. The work may be of interest to computational chemists and drug designers, but the current evidence base is too thin to establish the method's effectiveness beyond a proof-of-concept anecdote.
- **Who would be interested in the results, and why** Computational chemists and structural biologists working on IDP drug discovery, particularly those involved in virtual screening of large ligand libraries against conformational ensembles. Method developers in reinforcement learning applied to scientific computing may also find the algorithmic adaptation relevant. The potential to reduce computational cost in high-throughput docking could appeal to pharmaceutical researchers targeting IDPs, though the current abstract does not yet demonstrate practical utility at scale.
- **Major strengths** The problem addressed is well-recognized and practically important, as docking against large conformational ensembles is computationally prohibitive. The proposed approach, framing docking as a sequential decision problem with a reversible UCB strategy, is a creative and potentially efficient solution. The focus on the decision boundary between top ligands and the bulk is a sensible heuristic that could reduce redundant computations.
- **Major Concerns**  
  - **Concern ID** R1-M1  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Technical soundness  
    **Claim pointer** The abstract claims that the average docking number per ligand can be "greatly reduced" while performance is "merely slightly affected" in the c-Myc example.  
    **Evidence pointer** Abstract text; location not provided  
    **Concern** No quantitative data are provided to support the claimed reduction in docking number or the extent of performance change. Without specific numbers, such as the fold reduction in docking calls, the change in enrichment or ranking metrics, and the variance across replicates, the claim is unverifiable.  
    **Why it matters** The central value proposition of the method rests on this trade-off between computational savings and accuracy. If the reduction is modest or the performance loss is substantial, the method's utility is questionable. The abstract must report concrete metrics to allow assessment.  
    **Resolution test** Provide exact values for average docking number per ligand before and after the algorithm, the performance metric used (e.g., enrichment factor, AUC, or hit rate), and the difference relative to a baseline (e.g., exhaustive docking or random sampling). Include confidence intervals or standard deviations if replicates were performed.  
  - **Concern ID** R1-M2  
    **Severity** Major  
    **Blocking** Yes  
    **Axis** Technical soundness  
    **Claim pointer** The abstract implies that the reversible UCB algorithm is generally applicable to IDP virtual screening, but no comparison to existing methods is described.  
    **Evidence pointer** Abstract text; location not provided  
    **Concern** The abstract does not mention any baseline or alternative approach, such as ensemble docking with clustering, greedy selection, or other active learning strategies. Without a comparative evaluation, it is unclear whether the proposed method offers any advantage over simpler heuristics.  
    **Why it matters** A new algorithm must demonstrate superiority or at least parity with existing methods to justify its adoption. The absence of baselines makes the claimed efficiency gains uninterpretable in context.  
    **Resolution test** Include a comparison against at least one standard baseline, such as random conformation selection or a fixed-order docking protocol, reporting the same performance and cost metrics. Discuss statistical significance if applicable.  
  - **Concern ID** R1-M3  
    **Severity** Major  
    **Blocking** No  
    **Axis** Reproducibility  
    **Claim pointer** The abstract describes a "reversible upper confidence bound" algorithm but provides no details on its implementation.  
    **Evidence pointer** Abstract text; location not provided  
    **Concern** The algorithm's design, including how "reversibility" is defined, how the UCB is computed, and how the decision boundary is identified, is not specified. This prevents replication or even a clear understanding of the method's novelty.  
    **Why it matters** Reproducibility is a core requirement for scientific claims. Without algorithmic details, other researchers cannot implement or test the method, limiting its impact.  
    **Resolution test** Provide a full description of the algorithm, including pseudocode, hyperparameters, and the specific docking protocol used. If the full manuscript contains this, the abstract should at least reference the relevant section or supplementary material.  
  - **Concern ID** R1-M4  
    **Severity** Major  
    **Blocking** No  
    **Axis** Generalizability  
    **Claim pointer** The abstract suggests the method is "highly efficient in solving the bottleneck" for IDP virtual screening, but only one example (c-Myc) is mentioned.  
    **Evidence pointer** Abstract text; location not provided  
    **Concern** The demonstration on a single target, c-Myc, is insufficient to support broad claims about IDP drug design. IDPs vary in ensemble size, conformational diversity, and ligand binding modes, which could affect algorithm performance.  
    **Why it matters** Overgeneralization from a single case can mislead readers about the method's robustness. The abstract should either temper the claim or present evidence from multiple targets.  
    **Resolution test** Either revise the claim to be specific to the c-Myc case or add results from additional IDP targets with different ensemble characteristics. If the full manuscript includes such data, the abstract should reflect that scope.
- **Minor Comments**  
  - **Concern ID** R1-m1  
    **Severity** Minor  
    **Axis** Clarity  
    **Affected element** Terminology  
    **Evidence pointer** Abstract text  
    **Issue** The term "reversible upper confidence bound" is not defined, and "reversible" is ambiguous in this context.  
    **Required correction** Define the term in the abstract or clarify what aspect of the algorithm is reversible, such as allowing revisiting conformations or undoing prior decisions.  
  - **Concern ID** R1-m2  
    **Severity** Minor  
    **Axis** Readability  
    **Affected element** Abstract structure  
    **Evidence pointer** Abstract text  
    **Issue** The abstract moves from problem statement to method to a single example without stating the performance metric used, making the result hard to interpret.  
    **Required correction** Specify the performance metric (e.g., enrichment factor, ROC AUC) and the computational cost metric (e.g., number of docking runs) explicitly.  
  - **Concern ID** R1-m3  
    **Severity** Minor  
    **Axis** Context  
    **Affected element** Related work  
    **Evidence pointer** Abstract text  
    **Issue** No mention of prior work on active learning or reinforcement learning for docking, which would help position the novelty.  
    **Required correction** Add a sentence referencing relevant prior methods and how this approach differs, if space permits.
- **Technical failings that need to be addressed before the case is established** R1-M1 and R1-M2 are blocking because the core claims of efficiency and effectiveness are unsupported by quantitative evidence and lack baseline comparison. R1-M3 is also critical for reproducibility, though it may be addressed by full manuscript details. R1-M4 is important for scope but not necessarily blocking if the abstract is revised to be more cautious.
- **Assessment against Nature-style criteria**  
  - **Originality** The idea of applying a UCB-style algorithm to docking ensemble selection is novel in the context of IDP virtual screening, though the underlying reinforcement learning framework is not new. The originality is moderate and could be strengthened with clearer differentiation from existing active learning approaches.  
  - **Scientific importance** The problem of computational cost in IDP docking is significant for drug discovery, and a method that reduces cost without major accuracy loss would be valuable. However, the current evidence does not yet demonstrate that this method achieves that goal at a level that would change practice.  
  - **Interdisciplinary readership** The work bridges machine learning and computational chemistry, which could appeal to readers in both fields. The abstract is accessible to a broad scientific audience, but the lack of technical detail limits its utility for specialists.  
  - **Technical soundness** The algorithmic concept is plausible, but the absence of quantitative results, baselines, and implementation details means technical soundness cannot be assessed from the abstract alone.  
  - **Readability for nonspecialists** The abstract is generally clear in its problem statement and high-level approach, but terms like "reversible upper confidence bound" and the lack of concrete outcomes reduce accessibility.  
- **Recommendation posture** Currently not established from the provided evidence. The abstract presents a promising idea but lacks the quantitative and comparative data necessary to support its claims. I would be supportive if the full manuscript provides detailed results, baselines, and algorithmic specifics that address the blocking concerns.

## Risk / unsupported claims
- The claim that the average docking number per ligand is "greatly reduced" is unsupported without specific numbers.
- The claim that performance is "merely slightly affected" is unsupported without a defined performance metric and comparison.
- The general statement that the method is "highly efficient in solving the bottleneck" for IDP virtual screening is unsupported by evidence from a single example.
- The novelty and effectiveness of the "reversible UCB" algorithm cannot be evaluated without implementation details or comparison to existing methods.